Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting nonalloimmune-dependent pathways

J A Kobashigawa1

  • 1University of California School of Medicine, UCLA Heart Transplant Program, USA.

Transplantation Proceedings
|January 1, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review.

Transplantation proceedings·2017
Same author

Combined Heart and Kidney Transplantation: A 23-Year Experience.

Transplantation proceedings·2017
Same author

Tacrolimus-associated Diffuse Gastrointestinal Ulcerations and Pathergy: A Case Report.

Transplantation proceedings·2017
Same author

Report from a forum on US heart allocation policy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

Left ventricular assist device in patients with body mass index greater than 30 as bridge to weight loss and heart transplant candidacy.

Transplantation proceedings·2014
Same author

Everolimus in heart transplantation: does it finally have a home?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Medical therapies show limited success in preventing cardiac allograft vasculopathy (TCAD). Early intervention at transplantation is crucial, with retransplantation being the only current option for severe cases.

Area of Science:

  • Cardiology
  • Transplantation Immunology
  • Vascular Biology

Background:

  • Cardiac allograft vasculopathy (TCAD) is a major long-term complication following heart transplantation.
  • Current medical therapies have shown limited efficacy in preventing TCAD development, though some may slow its progression.

Purpose of the Study:

  • To review the current landscape of medical and surgical interventions for TCAD.
  • To highlight the critical timing for interventions and the role of retransplantation.

Main Methods:

  • Review of existing literature on TCAD treatment and prevention strategies.
  • Analysis of outcomes for medical therapies, revascularization procedures, and retransplantation.

Main Results:

Related Experiment Videos

  • Early interventions like diltiazem, pravastatin, and photopheresis can slow TCAD but not prevent it.
  • Revascularization procedures (angioplasty, CABS) offer palliative care and are not universally applicable.
  • Retransplantation is the sole effective treatment for severe TCAD, with acceptable outcomes for the second graft.

    • Conclusions:

    • Interventions for TCAD must commence at the time of initial transplantation.
    • Heart retransplantation is a viable option for severe TCAD, despite ethical considerations regarding organ scarcity.